New ACS Guidelines Take Firmer Stance on PSA Screening (+++++)

New ACS Guidelines Take Firmer Stance on PSA Screening With growing confidence that the benefits outweigh the risks, the American Cancer Society now calls for men to have routine prostate cancer screening. https://www.medscape.com/viewarticle/new-american-cancer-society-guidelines-take-firmer-stance-2026a10017j0?ecd=wnl_tp10_daily_261114_MSCPEDIT_etid8898500&uac=148436CN&impID=8898500 Among the 10 main recommendations, the group also advises repeat testing 2 weeks to 3 months later for men with PSA levels of 3 ng/mL or higher to confirm persistent elevations before further evaluation. The recommendations are a major departure from the group’s last guidelines in 2010, which were far less prescriptive and recommended that men be told about the uncertainties, risks, and potential benefits of screening, and then make a decision with their healthcare provider about going forward. 2Obesity, Sugar, and Metabolism in the Era of GLP-1s Researchers find a link between intestinal fructose metabolism and fat absorption, opening possibilities for new interventions in the metabolic cascade causing obesity. https://www.medscape.com/viewarticle/obesity-sugar-and-metabolism-era-glp-1s-2026a10017k2?ecd=wnl_tp10_daily_261114_MSCPEDIT_etid8898500&uac=148436CN&impID=8898500 GLP-1s have come to dominate the conversation around weight loss. But researchers like Hosung Bae, PhD, remain curious about the mechanisms underlying obesity. Among his persistent questions: How do organs coordinate the metabolism of nutrients? Intestinal fructose metabolism, for instance, can protect the liver by minimizing its exposure to fructose — a driver of fat production in the organ. Bae, an assistant professor in the Division of Endocrinology and Metabolism at the University of Iowa in Iowa City, wanted to understand more about the effects of the breakdown of fructose in the intestine. 3Exams Under Anesthesia: Obtain Explicit Consent https://www.medscape.com/viewarticle/exams-under-anesthesia-obtain-explicit-consent-says-ethicist-2026a10013n6?ecd=wnl_tp10_daily_261114_MSCPEDIT_etid8898500&uac=148436CN&impID=8898500 For decades, medical educators relied on the availability of anesthetized, unknowing patients’ bodies to train medical students how to perform sensitive exams, including those of the pelvis, rectum, prostate, and breast. Patients, students, clinicians and society are all harmed by these covert exams. A commitment to the essential practice of informed consent makes it possible to end these exams. 4Is It Time to Rename "Heart Failure"? https://www.medscape.com/viewarticle/much-about-heart-failure-has-evolved-should-its-name-2026a10017sp?ecd=wnl_tp10_daily_261114_MSCPEDIT_etid8898500&uac=148436CN&impID=8898500 At the moment, “failure” is the only option. Jane Ogden, PhD “You know what that means for something to fail: you failed your exams, or your marriages failed, or your fridge has failed,” said Jane Ogden, PhD, emeritus professor of health psychology at the University of Surrey in Guildford, England. “You know what that word means, and so they then use it in a medical setting, and it brings up all those other experiences that you’ve had with that word.” And so the debate over the term “heart failure” continues. 52 Trials Show Promise for Reductions in Serum Triglycerides https://www.medscape.com/viewarticle/two-trials-show-promise-major-reductions-serum-triglycerides-2026a10018cg?ecd=wnl_tp10_daily_261114_MSCPEDIT_etid8898500&uac=148436CN&impID=8898500 CHICAGO — A monoclonal antibody targeting ANGPTL4, one of a family of proteins that regulate lipoprotein lipase — a principal enzyme involved in hydrolyzing triglycerides (TGs) — reduced TG levels by up to 70% in those with severe hypertriglyceridemia, according to a dose-ranging phase 2b trial. The data were published online in The New England Journal of Medicine simultaneously with their late breaker presentation at the American Heart Association (AHA) Scientific Sessions 2026. Immediately following this study, called TYDAL-TIMI 78, a second AHA meeting late breaker associated a CRISPR-Cas9 gene editing therapy with an up to 85% reduction in TG levels. The phase 1b study included only 10 patients, but the treatment was well tolerated and nine patients had a major response.